Serum Institute of India CEO Adar Poonawalla on Tuesday said the company plans to launch its indigenously-developed vaccine to treat cervical cancer in women later this year Serum Institute of India CEO Adar Poonawalla on Tuesday said the company plans to launch its indigenouslydeveloped vaccine to treat cervical cancer in women later this year. The Drugs Controller General of India (DCGI) on Tuesday granted market authorisation to Serum Institute of India (SII) to manufacture the indigenously-developed India's first Quadrivalent Human Papillomavirus vaccine (qHPV) against cervical cancer. In response to the approval by the drug regulator, Poonawalla in a tweet said, "For the first time there will be an Indian HPV vaccine to treat cervical cancer in women that is both affordable and accessible. We look forward to launching it later this year and we thank the #DCGI @MoHFW_INDIA for granting approval today." The approval by the drug regulator of SII's anti-cancer vaccine followed recommendation by the Subject Expert Committee (SEC) on COVID-19 of the CDSCO on June 15. The company had applied to the DCGI seeking market authorisation of the qHPV after the phase 2/3 clinical trial was completed with support of the Department of Biotechnology. Cervical cancer in India ranks as the second most frequent cancer among women between 15 and 44 years of age.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!